BioCentury
ARTICLE | Finance

Re-upping in Israel

No safety net, no problem for OrbiMed's new Israel fund

May 30, 2016 7:00 AM UTC

OrbiMed Advisors is coming back for seconds in Israel with a $307 million fund focused on the country. This time, the Israeli government is not providing a safety net, but many of the original LPs returned in hopes that the firm can generate more exits like cCAM Biotherapeutics Ltd.

OrbiMed Israel Partners II will invest in about 20 healthcare companies. The fund is agnostic to stage of development. Areas of interest include therapeutics, digital health, devices and diagnostics...